IL17A and psoriasis: The blockade of the interleukin (IL)‐17 signalling pathway has revolutionized the treatment of psoriasis with agents such as ixekizumab, and secukinumab (IL‐17A inhibitors), brodalumab (IL‐17 receptor inhibitor) and bimekizumab (IL‐17A and IL‐17F inhibitor).